Loading...
Metagenomi, Inc. Common Stock
MGX•NASDAQ
Healthcare
Biotechnology
$1.76
$0.16(10.00%)
U.S. Market opens in 3h 33mMetagenomi, Inc. Common Stock (MGX) AI-Powered Stock Analysis
See how Metagenomi, Inc. Common Stock scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMetagenomi, Inc. Common Stock (MGX) Stock Overall Grade
Metagenomi, Inc. Common Stock’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Metagenomi, Inc. Common Stock's overall stock rating.
Forecast
C+Score
52/100Financial Growth
B+Score
75/100Fundamental Growth
DScore
37/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
B+Score
75/100Metagenomi, Inc. Common Stock (MGX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (75/100, B+) and Fundamental Growth (37/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Metagenomi, Inc. Common Stock stock grade, including financials, comparisons, and forecasts.